Neurogene
New York, New York, United States · Biotechnology, Health Care, Other
Neurogene Inc. is a clinical-stage company dedicated to bringing life-changing genetic medicines to patients and families affected by rare neurological diseases. The company focuses on developing novel approaches and treatments to overcome the limitations of conventional gene therapy in central nervous system disorders.
Key facts
- Headquarters
- New York, New York, United States
- Employees
- 110
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (NGNE)
- Website
- neurogene.com
- Company page
Recent activity at Neurogene
- : SEC 8-K (1.01): On June 30, 2026, Neurogene Inc. entered into a Material Definitive Agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC to issue and sell 3,500,000 shares of its common stock at a public offering price of $30.00 per share. Additionally, the Company is offering pre-funded warrants to purchase up to 666,666 shares at a nearly equivalent price, along with an option for underwriters to purchase an additional 624,999 shares, fully exercised on July 1, 2026. The expected net proceeds from the offering, including the exercised option, are approximately $134.8 million, with closing expected on July 2, 2026. The agreements include specific terms on the exercise of warrants and indemnification of the underwriters against certain liabilities.
- : SEC 8-K (8.01): On June 29, 2026, Neurogene Inc. announced positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401 gene therapy for treating females with Rett syndrome. This event highlights significant advancements in their research and development efforts, particularly in addressing this rare neurological condition. The company has shared a presentation (Exhibit 99.2) with detailed findings, emphasizing the potential impact of the therapy on affected patients. As part of their commitment to transparent communication, a related press release (Exhibit 99.1) was also issued on the same date.
- : SEC 8-K (7.01): On June 8, 2026, Neurogene Inc. issued a press release regarding the completion of dosing in its Embolden TM registrational trial for NGN-401, aimed at treating Rett syndrome. This trial milestone is significant as it brings the company closer to potential market approval for this therapeutic indication. Additionally, an updated corporate presentation was posted on the company's website on the same date, which may provide further insights into the company's strategic direction and recent developments. The information from the press release and corporate presentation is deemed important for security holders as it outlines advances in pipeline development and corporate strategy.
- : Neurogene Appoints Christy Shafer as Chief Commercial Officer
- : SEC 8-K (5.02): Effective April 20, 2026, Neurogene Inc.'s Board of Directors appointed Christine Mikail, the Company’s President and Chief Financial Officer, as a Class II director following the expansion of the Board to seven members. This appointment fills a vacancy and her term will expire at the 2028 annual meeting of stockholders. Ms. Mikail has extensive experience in the biotech industry and has been with Neurogene since December 2023. Notably, she played a significant role in raising $362 million during the initial public offering of Axovant Sciences. She was selected for her expertise and knowledge of the Company, and will not receive additional compensation for her directorship. This change reflects a strategic move to strengthen the Board's capabilities to navigate the company's future challenges.
- : SEC 8-K (7.01): On February 26, 2026, Neurogene Inc. announced in a press release that its investigational gene therapy, NGN-401, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for treating Rett syndrome. This designation is a significant development as it provides a faster track for drug approval and development. The announcement aligns with ongoing efforts to enhance the therapeutic potential for patients with this challenging condition, and the details are included in Exhibit 99.1 attached to the filing, which confirms the company's commitment to advancing innovative treatment options.
- : SEC 8-K (7.01): On January 12, 2026, Neurogene Inc. issued a press release detailing recent corporate updates and expected milestones for the forthcoming year, highlighting strategic initiatives and goals. Additionally, the Company released an updated corporate presentation on its website on the same date, which is intended to provide further insights into its operational strategies and projections. The disclosures are part of complying with Regulation FD, ensuring that all investors have equal access to important company information. These updates mark a significant communication effort aimed at engaging with stakeholders regarding the Company’s future direction and initiatives.
- : SEC 8-K (7.01): On November 12, 2025, Neurogene Inc. issued a press release highlighting positive interim clinical data from its ongoing Phase 1/2 trial of NGN-401 gene therapy, specifically targeting the pediatric cohort aged 4-10 with Rett syndrome. This announcement is significant for stakeholders as it indicates progress in a critical therapeutic area. Alongside the press release, the Company made a corporate presentation available on its website, detailing the clinical data. The event date of November 12 is crucial as it reflects recent advancements in the Company's clinical efforts, potentially impacting investor sentiment and future funding opportunities.
- : SEC 8-K (7.01): On November 6, 2025, Neurogene Inc. announced the dosing of the first patient in the Embolden TM registrational trial for NGN-401, aimed at treating Rett syndrome. This significant milestone in the clinical trial process marks an important step in the company's development of therapies for rare neurological conditions. In addition, a corporate presentation updating ongoing enrollment and dosing details for the trial was made available on their website the same day. This press release and presentation are critical for stakeholders following Neurogene's progress in clinical research and potential market implications.
- : Neurogene Inc. announces positive interim data for NGN-401 gene therapy aimed at treating Rett syndrome.
Neurogene funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | IPO | $105.0M |
| Dec 2020 | Venture | $69.0M |
| Feb 2019 | Venture | $37.5M |
Leadership
- Rachel McMinn, Executive Officer, Director
- Robert Baffi, Director
- Stephen Biggar, Director
- Cory Freedland, Director
- Srdjan Stankovic, Director
- Caroline Stout, Director
- Arvind Sreedharan, Senior Vice President, Business Operations
- Ricardo Jimenez, Senior Vice President, Technical Operations
- Christine Mikail, President
- Christy Shafer, Chief Commercial Officer
- Julie Jordan, M.D., Chief Medical Officer
- Christine Cvijic, Executive Officer
Verified email and direct lines for Neurogene’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Neurogene in the news
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Oct 05, 2026)
- Neurogene Reaches Accord With FDA on Plan for Registrational Trial for Rett Syndrome Gene Therapy NGN-401 - CGTLive® (Oct 09, 2025)
- Neurogene secures $200M ahead of anticipated study readout - BioPharma Dive (Nov 04, 2024)
- Neurogene, a clinical trial, and the race to the bottom of gene therapy - STAT (Nov 14, 2024)
- ASGCT: Neurogene details new safety measures after young patient's death in AAV gene therapy trial - Fierce Biotech (May 16, 2025)
- Patient dies in Neurogene’s Phase I/II Rett syndrome trial - Clinical Trials Arena (Nov 22, 2024)
- A live webcast will feature Neurogene on Sept. 15. - Stock Titan (Sep 08, 2026)
- Neurogene’s Rett Syndrome Gene Therapy NGN-401 Demonstrates Efficacy in Low-Dose Cohort, But Serious Adverse Event in High-Dose Group Raises Concerns - CGTLive® (Nov 13, 2024)
Companies similar to Neurogene
- Healx · Biotechnology, Health Care, Other, Therapeutics
- CERo Therapeutics Holdings · Biotechnology, Health Care, Other, Therapeutics
- EXICURE, INC. · Biotechnology, Health Care, Other, Therapeutics
- Compugen · Biotechnology, Health Care, Other, Therapeutics
- Vor Bio · Biotechnology, Health Care, Other, Therapeutics
About Neurogene: questions and answers
What does Neurogene do?
Neurogene Inc. is a clinical-stage company dedicated to bringing life-changing genetic medicines to patients and families affected by rare neurological diseases. The company focuses on developing novel approaches and treatments to overcome the limitations of conventional gene therapy in central nervous system disorders.
Where is Neurogene headquartered?
Neurogene is headquartered in New York, New York, United States.
How many employees does Neurogene have?
Neurogene has about 110 employees.
Has Neurogene raised funding?
Yes. Fundz has recorded 3 funding events for Neurogene. The most recent, IPO of $105.0M, was in Mar 2024.
Who leads Neurogene?
Arvind Sreedharan is a Senior Vice President, Business Operations at Neurogene.
What is the latest news on Neurogene?
On Jul 02, 2026, SEC 8-K (1.01): On June 30, 2026, Neurogene Inc. entered into a Material Definitive Agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC to issue and sell 3,500,000 shares of its common stock at a public offering price of $30.00 per share. Add
Is Neurogene a public company?
Yes. Neurogene is publicly traded under the ticker NGNE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy